No description available.

Introduction: Osteoporotic fractures, a major public health problem in aging populations, can lead to increased disability and mortality. Though rheumatoid arthritis (RA) patients have a higher risk for fractures than healthy populations, it is not known how hip structural geometry and body composition, two factors associated with bone strength, affect fracture risk in this population. The overall goal of this dissertation is to examine the association between RA, fracture, hip structural geometry, and body composition, in the participants of the Women's Health Initiative (WHI).Methods: The association between probable RA and fracture risk was tested using the entire WHI cohort (n=161,808). The association between probable RA and hip structural geometry was tested, both cross-sectionally and longitudinally, in a smaller sample (n=11,020) of participants from the WHI Bone Density Centers (WHI-BMD). The last study, testing the association between probable RA and body composition was also conducted in the WHI-BMD cohort.Results: In comparison to the non-arthritic group, the probable RA group had a significant 50%, 2-fold, and 3-fold increase in any, spine, and hip fracture, respectively. The association was not mot modified by age or ethnicity, but glucocorticoid use altered the association between RA and spine fractures. In terms of geometry, the probable RA had a significantly lower (p<0.05) mean hip BMD, outer diameter, cross-sectional area, and section modulus at the narrow neck region compared to control groups, indicating reduced bone strength. Body composition changes were present between the probable RA and the control group, with the probable RA group having statistically lower estimate of lean mass and statistically higher estimates of fat mass compared to the non-arthritic control group cross-sectionally and over the study.Conclusion: These studies confirm the increased risk for fracture among RA patients, while providing evidence that RA alters bone strength, especially at the hip, and negatively effects body composition by reducing lean mass and increasing fat mass. Additional research is needed link structural geometry and body composition to bone strength to lead to tailored interventions to minimize decreases in bone strength in this high fracture risk population.

Recorded by Eugene Barsky, Physiotherapy Outreach Librarian, UBC / This is a Systematic Review Presentation titled - "The Effects of Yoga on People with Arthritis: A Systematic Review", created by Master of Physical Therapy Graduating Students, University of British Columbia - 2006, Presented on September 14-15, 2006 , Vancouver, BC, Canada

The inflammatory response caused by the deposition of crystals of monosodium urate monohydrate (MSUM) and calcium pyrophosphate dihydrate (CPPD) in the synovial fluid of joints, results from the interaction of the crystals with neutrophils. Neutrophils (whose function in the body is to remove hazardous microorganisms and inflammatory debris) are activated by the binding of the crystals to the neutrophil cellular membrane, which leads to respiratory burst activity, engulfment of the crystals and release of proteolytic enzymes. Furthermore, we have found that crystals delay the normal “cell death program” or apoptosis, thus allowing for the accumulation of these cells, and extended inflammatory responses. Very little is known about the mechanisms of activation and delay of apoptosis, however, bcl-2 family proteins have been implicated in the control of neutrophil apoptosis. This study helps to define the role of several bcl-2 family proteins (both pro- and anti-apoptotic) by examining the differential expression of these proteins upon stimulation with crystals. Subsequent identification of signaling targets that function to regulate this process in response to crystals could lead to potential therapeutics for crystal-induced inflammatory diseases.

BACKGROUND: Parents of children with juvenile idiopathic arthritis (JIA) are often forced to make trade-offs between the effectiveness, convenience, safety, and cost of drug treatments for their child. METHODS: A discrete choice experiment was administered to parents of children with JIA to determine their preferences for drug treatments. Multinomial logit regression was used to estimate part-worth utilities and willingness-to-pay. RESULTS: Participation in daily activities was the most important attribute, followed by child reported pain. Child age, gender, years with JIA, and household income had the greatest impact on preferences. Parents’ were willing to pay $2,080 to switch from a drug representing methotrexate to etanercept (95% CI $698, $4,065). CONCLUSIONS: Parents of children with JIA have the highest maximum willingness-to-pay for drug treatments that improve daily functioning and reduce pain. Cost is a significant factor in the decisions that parents make surrounding the best treatment for a child.

BACKGROUND: Parents of children with juvenile idiopathic arthritis (JIA) are often forced to make trade-offs between the effectiveness, convenience, safety, and cost of drug treatments for their child. METHODS: A discrete choice experiment was administered to parents of children with JIA to determine their preferences for drug treatments. Multinomial logit regression was used to estimate part-worth utilities and willingness-to-pay. RESULTS: Participation in daily activities was the most important attribute, followed by child reported pain. Child age, gender, years with JIA, and household income had the greatest impact on preferences. Parents’ were willing to pay $2,080 to switch from a drug representing methotrexate to etanercept (95% CI $698, $4,065). CONCLUSIONS: Parents of children with JIA have the highest maximum willingness-to-pay for drug treatments that improve daily functioning and reduce pain. Cost is a significant factor in the decisions that parents make surrounding the best treatment for a child.

Rheumatoid arthritis is an autoimmune disease that can cause chronic inflammation of the joints and other areas of the body. Neutrophils contribute to the pathogenesis of arthritis, and are recruited to the site of inflammation by chemokines. CXCL8/IL-8 is a member of a sub-family of chemokines (ELR+CXC chemokines) that activate and attract neutrophils through the CXCR1 and CXCR2 receptors. Our lab developed a high affinity human CXCR1/CXCR2 antagonist, called human CXCL8(3-72)K11R/G31P (hG31P). This antagonist has been shown to be highly effective in blocking ELR+CXC chemokine-driven neutrophilic inflammation. In this study we looked at the therapeutic effect of blocking ELR+CXC chemokine receptors (CXCR1 and CXCR2) in an experimental model of arthritis. We induced type II collagen (CII)-induced arthritis (CIA) in mice and treated them with hG31P after the onset of disease. The parameters we looked at to assess disease severity were clinical scores (paws were graded on the severity of edema), clinical measurements (measuring inflammation by change in circumference of paw), serum levels of anti-CII antibodies, and inflammatory cytokines mRNA (IL-1β, TNF, KC, and MIP-2) and protein levels (IL-1β, IL-6, KC, and MIP-2) in paw tissue. Initially, when we analyzed all mice together, we were unable to see a change in clinical scores and measurement when CIA mice were treated with hG31P. All CIA mice did not develop arthritis simultaneously, but rather in a serendipitous fashion; therefore we subdivided our mice and analyzed data from mice that developed arthritis early versus those that developed it late. Treatment with hG31P in mice that developed arthritis early (within 5 weeks of initial CII injection) significantly reduced clinical scores (p=0.02) in one, but not both, of our experiments. When CIA mice were treated with hG31P we saw a significant reduction (p<0.05) in CII-specific IgG1 and MIP-2 protein levels in one of our experiments. Our results were variable and we did not see these changes in our other experiment. Treatment of CIA mice with G31P did not significantly affect inflammatory cytokine mRNA levels in the paws. During this study we found the production of anti-hG31P antibodies in our hG31P-treated mice. We used a Ca2+ influx assay to determine if these hG31P antibodies were neutralizing. When these antibodies were non-neutralizing we were able to see a significant reduction in the clinical scores (p=0.02) of our hG31P-treated CIA mice (that had developed early-onset arthritis) when compared to our saline-treated CIA mice. In the experiment in which we detected significant levels of neutralizing anti-hG31P antibodies, treatment with hG31P did not affect the clinical scores of our CIA mice. Although we cannot definitively say that hG31P has a therapeutic effect in CIA, we believe this line of research merits further investigation. Our research suggests to us that after some experimental refinement and reduction of the immune response mounted to hG31P, there could still be potential for hG31P to have a therapeutic effect in arthritis.

Aim: To describe the predictive validity of reaching low disease activity (LDA) at 1 year on future disability and joint damage in patients with early rheumatoid arthritis (ERA). Methods: First a systematic literature review of prognostic studies assessing the association between disease activity and functional or radiographic outcomes in ERA was performed. Then data from the Study Of New-Onset RA (SONORA) were used to evaluate the impact of year-one LDA on 3-year disability and 2-year radiographic progression using multivariate regression analyses. Results: Our review demonstrated evidence for relationship between baseline disease activity and future disability and join damage. However evidence for the impact of early treatment response on long-term outcomes in ERA is sparse. Analysis of 984 patients showed year one LDA predicts lower HAQ (p<.0001) and less damage (p=0.04) in future. Conclusion: Reaching LDA early is associated with better long-term functional and radiographic outcomes in patients with early RA.

Aim: To describe the predictive validity of reaching low disease activity (LDA) at 1 year on future disability and joint damage in patients with early rheumatoid arthritis (ERA). Methods: First a systematic literature review of prognostic studies assessing the association between disease activity and functional or radiographic outcomes in ERA was performed. Then data from the Study Of New-Onset RA (SONORA) were used to evaluate the impact of year-one LDA on 3-year disability and 2-year radiographic progression using multivariate regression analyses. Results: Our review demonstrated evidence for relationship between baseline disease activity and future disability and join damage. However evidence for the impact of early treatment response on long-term outcomes in ERA is sparse. Analysis of 984 patients showed year one LDA predicts lower HAQ (p<.0001) and less damage (p=0.04) in future. Conclusion: Reaching LDA early is associated with better long-term functional and radiographic outcomes in patients with early RA.

Rheumatoid arthritis (RA) is a chronic inflammatory disease with an unknown aetiology characterized by joint destruction. Both genetic and environmental factors contribute to the disease development with HLA-DRB1* alleles and smoking identified as most important. The disease is characterized by the presence of autoantibodies, originally by rheumatoid factor (RF) and more recently by anti citrullinated protein/peptide antibodies (ACPA) and antibodies against carbamylated peptides (CarP). These autoantibodies are present, not only after the onset of disease, but also prior to the onset of symptoms. The development of RA is a gradual process lasting several years before the onset of any joint symptom, but when and if there is a temporal difference in the development both between and within the different antibody systems is currently unknown. B-cells produce the antibodies, and a subset of B-cells, i.e., B-regulatory (Breg) cells, produces interleukin-10, and thus have the ability to down-regulate pro-inflammatory cytokines. Whether the Breg cells are involved in the pathogenesis of RA is, as yet, unknown. The aim of this thesis was to increase knowledge of the pathophysiological processes in the development of RA through identification of factors involved. The analyses involved detection of autoantibodies to post-translationally modified peptides/proteins in addition to RF isotypes, cell surface markers on immune cells in asymptomatic individuals, who have an increased risk of developing RA. In a co-analysis of the registers of patients with RA attending the Department of Rheumatology, with the registers from population based screening programmes within the Biobank of Northern Sweden, blood samples collected from individuals prior to the onset of symptoms were identified, as were those from population control subjects. A cohort of pre-symptomatic individuals also donated samples at the time of receiving a diagnosis of RA. First-degree relatives (FDR) of patients with RA were also identified and included for analyses. The levels of ten different ACPAs, i.e., (fibrinogen (Fib) α563-583(573), Fibα580-600(591), Fibβ62-81a(72), Fibβ62-81b(74), Fibβ36-52, a-enolase (CEP-1), triple helical collagen type II (citC1III), filaggrin (Fil307-324), vimentin (Vim) 2-17, and Vim60-75) were measured using the ImmunoCAP ISAC system (Phadia/ThermoFischer, Uppsala, Sweden) in blood samples from individuals before the onset of symptoms and when diagnosed with RA in comparison with those in population based controls. In a subset of samples, the levels of anti-CarP antibodies were measured using ELISA coated with anti-CarP-FCS, as well as analysis of RF of IgM, IgG and IgA isotype using the EliA assay (Phadia, Uppsala, Sweden). Breg cells were analysed both with and without stimulation ex vivo along with other cell types using flow cytometry in samples from patients with RA, their first degree relatives (FDR) and healthy controls. In paper I it was shown that levels of ACPA were initially restricted to a few antibodies but disseminated over time to involve additional different antibodies. The levels of antibodies to CEP-1, Fibß36-52, and filaggrin were significantly increased. In paper II, anti-CarP antibodies were positive in 5-13% of the individuals negative for the various ACPA studied. The presence of anti-CarP antibodies was significantly related to radiological destruction of joints at baseline, at follow-up after 24 months and to the radiological progress between baseline and 24months. In paper III, the relationships between the frequencies of RF isotypes, the ten different ACPA, anti-CCP2 and anti-CarP antibodies before the onset of any symptoms and the presence of certain combinations of antibodies were associated with a very high risk of developing RA. In paper IV Breg cells from patients with RA are functionally impaired and FDR showed a similar pattern by responding less to stimulation ex vivo than cells from healthy controls. In conclusion, individuals who subsequently develop RA have an increased number and amount of ACPAs, anti-CarP antibodies and RF of IgM, IgG and IgA isotype, several years before symptom onset. Most of the different antibodies analysed remain associated with disease development after adjustments for each separate antibody. In FDRs, Breg cells were functionally altered in that they produce less IL-10 and consequently contribute to a more inflammation-prone status, as in their relatives with RA. These findings contribute to information about the development of RA as well as a given individual’s risk(s) of developing RA and its progression.